foryoupeptides

CITED LITERATURE

References

Every source cited across this desk, numbered and linked.

References

The numbered citations below are the complete source inventory for the ForYouPeptides research desk. Each entry corresponds to a bracketed number used in the text across all pages. Sources are drawn from peer-reviewed journals (primarily PubMed-indexed), an NCBI Bookshelf clinical reference, and systematic reviews. Priority was given to large randomised controlled trials and dedicated safety reviews that form the primary evidence base for semaglutide and tirzepatide.

Links resolve to PubMed entries or publisher pages where available. The renderer displays the full citation list below.

  1. Aronne LJ, et al. (SURMOUNT-5 Investigators). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. ↗
  2. Perkovic V, et al. (FLOW Trial Committees and Investigators). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024. ↗
  3. Lincoff AM, et al. (SELECT Trial Investigators). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. ↗
  4. Wilding JPH, et al. (STEP 1 Study Group). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. ↗
  5. Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021. ↗
  6. Gabery S, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020. ↗
  7. Marso SP, et al. (SUSTAIN-6 Investigators). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016. ↗
  8. Farzam K, Patel P. Tirzepatide (StatPearls). StatPearls [Internet], NCBI Bookshelf. 2024. ↗
  9. Zeng Q, et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023. ↗
  10. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. ↗
  11. Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021. ↗